Clay Siegall- Changing the Face of Healthcare Investment
There are many respected people in the world that are proud to be called legends in their area of operation. Clay Siegall is no stranger to such terms for his contributions to the therapy industry. He is the CEO of Seattle Genetics, a biotech company that focuses on the development of targeted therapy drugs. These are efficient drugs for diseases that have not seen any helpful improvements for many years. The company was formed in 1998 and it has gone on to develop the first FDA-approved antibody drug. It has also enjoyed great partnerships with drug manufacturers such as Pfizer, Bayer, and Genentech among others.
Clay Siegall inspiration to establish Seattle Genetics was his growing interest in medicine and the innovation power of technology, and desire to find solutions to diseases affecting humanity on daily basis. Due to the rampant cases of cancer infection and slow development of its cure, Mr. Siegall was interested in cancer treatment while in university. This interest was also fueled by realization that one of his family members was suffering from the condition and going through brutal treatment regimen. He went on to invest in Seattle Genetics and help many people suffering from cancer and related conditions.
He also served as a board of director of Ultragenyx Pharmaceutical, Washington Roundtable, and Alder BioPharmaceuticals. Clay dedicates his success to his love for education and hard work. He is a Ph.D. holder in Genetics from the George Washington University. He also an alumnus of the University of Maryland and a holder of a B.S in Zoology.
Clay Siegall advises entrepreneurs and scholars to learn as much as they can. He also advocates for constant interaction with experts in diverse fields one wants to major in and make the right decisions. Dr. Clay also articulates that collaborating with other companies is one of the key components of every business strategy. His company has been a success thanks to his involvement with other innovators in drug development sector. Through Seattle Genetics collaborators, the company has expanded its reach to technology and it has been able to source for new ideas and approaches to help its large clientele base.